Bio Pharma Dive
NOVEMBER 3, 2022
In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discussed how startups can navigate a challenging market as well as possible ripple effects from the new U.S. drug pricing law.
Pharmaceutical Technology
OCTOBER 31, 2022
After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results in older adults. There are currently five players in the race, with vaccines in Phase III of development from GlaxoSmithKline (GSK) , Pfizer , Johnson & Johnson , Moderna and Bavarian Nordic. However, recent data from GSK’s sub-unit vaccine, GSK-3844766A, have pushed the candidate to the top, with the highest efficacy demonstrated in a pivotal trial to date.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 31, 2022
Rheumatoid arthritis affects 1 in 100 people worldwide. It causes inflamed, painful and swollen joints, often in the hands and wrists, and can lead to loss of joint function as well as chronic pain and joint deformities and damage. What causes this condition has been unknown. [link] In our recently published study, my colleagues and […].
NPR Health - Shots
NOVEMBER 3, 2022
The updated recommendations seek to course correct after guidelines from 2016 were criticized for harshly limiting access to needed pain medication. (Image credit: Jose M.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
NOVEMBER 1, 2022
To some analysts, the recent acquisitions of Akouos and AGTC, as well as Astellas’ equity investment in Taysha, are a positive signal for an area of drug research that’s been “in investors' penalty box for much of 2022.
Pharmaceutical Technology
NOVEMBER 2, 2022
Pfizer has reported a 6% decline in revenue to $22.6bn in the third quarter (Q3) of 2022 as against $24bn in the same quarter last year. In the quarter, revenues rose 2% operationally on omitting contributions from Covid-19 therapies, Paxlovid and Comirnaty. Reduction in revenues from Comirnaty outside the US and reduced revenues for some Comirnaty-linked manufacturing works carried out on behalf of BioNTech, Xeljanz and Sutent worldwide were the key drivers that contributed to the revenue dec
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 4, 2022
Treatment will assist young people and children with symptoms of mild-to-moderate anxiety
Bio Pharma Dive
NOVEMBER 4, 2022
Competition is increasing behind newly approved drugs from Roche and J&J, while the long-term benefit of gene therapies for chronic blood disorders is being put to the test.
Pharmaceutical Technology
NOVEMBER 1, 2022
In a few weeks, the EU-funded research project Darwin EU will announce its first batch of data partners for the ambitious real-world data -driven Horizon 2020 project. This project centres around the use of electronic health records (EHRs) from different European countries to drive research and improve responses to expected and unexpected crises. A major objective of this project hinges on exploiting national EHR data to complete observational studies quicker than industry standards.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 2, 2022
Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition. [link] In a new study, published Thursday (27 October) in the journal Science, researchers identified a previously unknown class of DNA-damaging molecules, or genotoxins, […].
NPR Health - Shots
NOVEMBER 2, 2022
It could amount to the last round of huge settlements after years of litigation over the industry's role in an overdose crisis linked to more than 500,000 deaths in the U.S. over the past two decades.
Bio Pharma Dive
NOVEMBER 3, 2022
With public offerings difficult to pull off, Artiva is focusing its energy on a cancer drug deal with the German biotech.
Pharmaceutical Technology
NOVEMBER 3, 2022
Drug shortages continue affecting cardiovascular clinical practice across the world, reflecting rising demand and cost-effective manufacturing challenges. While the stock of currently affected drugs is expected to improve as production is increased in the near future, experts say it is likely that the cardiovascular sector will be particularly affected by such shortages in the long run as demand continues to grow from an aging population.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
Porous particles of silica made from purified sand could one day play a role in attempts to lose weight. Past clinical trials have already produced promising results, but the actual weight-lowering mechanism behind the potential treatment has been poorly understood. [link] To sift out the key variables, researchers have now tested a range of silica […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
STAT News
NOVEMBER 4, 2022
New data from Pfizer and BioNTech on their bivalent Covid-19 vaccine suggests the updated product may be more protective against more recent Omicron subvariants than the original version of the vaccine, the companies said in a statement released Friday. The companies said the levels of neutralizing antibodies that target the BA.4 and BA.5 subvariants of the SARS-CoV-2 virus were four-fold higher in people aged 55 and older who received the bivalent booster than in similarly aged people who recei
Bio Pharma Dive
OCTOBER 31, 2022
Bringing more diversity to clinical trials is a slow process and it takes time to get right. Learn how Worldwide Clinical Trials can diversify the reach of your orphan drug trial.
Pharmaceutical Technology
OCTOBER 31, 2022
Hoffmann-La Roche (Roche Canada) has received approval from Health Canada for Actemra IV (tocilizumab for injection) vials to treat Covid-19 patients. The treatment is indicated for adult Covid-19 patients who are on systemic corticosteroids and need additional oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 1, 2022
As drug companies have embarked on an initiative to launch affordable medicines for rare diseases in India, experts have called for using pharmacogenetics to develop treatments and whole genome sequencing to identify etiologies. “Although rare diseases have a huge impact when taken together, there is a significant gap between clinical interventions and basic research.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
STAT News
NOVEMBER 3, 2022
The journal Nature published today global consensus recommendations to end Covid-19 as a public health threat. It took a panel of almost 400 independent-thinking scientists, doctors, and representatives of community groups from more than 100 countries (we were among the co-chairs) some 14 months to develop and agree on these recommendations. There have been times when we wondered if it was worth the effort.
Bio Pharma Dive
OCTOBER 31, 2022
For the second time this year, the agency has put off a decision on Amicus' therapy for Pompe disease. European regulators are also reviewing the treatment and could soon issue an opinion.
Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Massachusetts Institute of Technology (MIT)’s Computer Science and Artificial Intelligence Laboratory (CSAIL) researchers have developed a system called ‘series elastic end effectors’ (SEED) that enable robots to use grabbed tools correctly and successfully. It was developed in partnership with the American Toyota Research Institute (a technology research unit of Toyota).
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 3, 2022
In a bid to control the microbial quality of pharmaceutical products, the Indian Pharmacopoeia Commission (IPC) has come out with a draft amendment to microbial contamination in non-sterile products in Indian Pharmacopoeia (IP) 2022. The new draft amendment released by IPC on October 26, 2022 introduced changes to enumeration of aerobic microorganisms present in the […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
NPR Health - Shots
NOVEMBER 2, 2022
Doctors say they are seeing an unprecedented number of cases. How concerned should parents be? Why are young children so vulnerable? What's causing this year's outbreak? We offer some answers.
Bio Pharma Dive
NOVEMBER 3, 2022
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.
Pharmaceutical Technology
NOVEMBER 4, 2022
Last week, after a tumultuous 45 days under Liz Truss’s control , the role of the UK’s Prime Minister (PM) was passed on to Rishi Sunak , in a bid to restore balance to the British economy. During her short reign, Truss’s cabinet had promised a £45 billion ($51.59 billion) mini-budget that included unfunded tax cuts for the rich, enacted a U-turn on an energy price freeze, and oversaw the largest drop in value for the British pound against the US dollar.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
High optimism prevails on the implementation of QR code which would aid faster traceability through the supply chain among Indian pharma. Nakul Pasricha, president, Authentication Solution Providers’ Association (ASPA), noted that a sharp spike was observed in the number of counterfeiting incidents related to pharma and medical products estimated as high as at 47 percent. […].
NPR Health - Shots
NOVEMBER 1, 2022
Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.
Bio Pharma Dive
NOVEMBER 2, 2022
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
Pharmaceutical Technology
NOVEMBER 1, 2022
FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. The Excellence Rankings celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognise the people and companies that are driving change.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 1, 2022
“Zombie cells” that contribute to age-related diseases also help heal damaged tissues, so wiping them out could come with major downsides, a new study suggests. The zombies, scientifically known as “senescent” cells, are cells that stop multiplying due to damage or stress but don’t die, according to the National Institute on Aging.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
362 
Let's personalize your content